Gene therapy offers people with rare bleeding disorder a new level of freedom
(BPT) - -
Stay updated with breaking news from Coagulation Disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A new review article illuminates why physicians should keep coagulation disorders in mind when evaluating patients with heavy abnormal uterine bleeding.
Havana, May 16 (Prensa Latina) The Cuban Hemophilia Society (SCH) has shown some progresses in medical and scientific works, and has a strategy for a better quality of life for people living with this disease.
Global biotechnology leader CSL (ASX: CSL) today announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B (congenital Factor IX ...
The first gene therapy for haemophilia B has been given conditional marketing authorisation in Europe by the European Commission.